cheap copies of its drugs particularly anti depressants paxil and wellbutrin and a weak dollar had hit profits but global sales were up 1 in 2004. the firm is confident its new drug pipeline will deliver profits despite the failure of an obesity drug. glaxo aims high after profit fall glaxosmithkline saw its profits fall 9 last year to 6.2bn 11.5bn but europe s biggest drugmaker says a recovery during 2005 is on the way. glaxo is relying on new treatments for conditions such as cancer diabetes depression hiv aids and allergies to lift the pace of sales growth after several disappointing years. mr garnier said the company had absorbed over 1.5bn of lost sales to generics but still managing to grow the business. however the firm discontinued development of an experimental treatment for obesity known as 771 after disappointing clinical trial results.